• Tues news: Prostate cancer trials to watch. Merck’s subcutaneous Keytruda. Apellis sees positive in Astellas CRL. Future of Medicare price negotiations. JNJ psoriasis results. See more on our front page

Departures HCV

























































Bye bye 2nd generation!! Only so much $s for R&D and it is now going into oncology. See ya Louie and Lootzie! Do not follow me to my new company and in our district this week there are 3 reps that have gone on to greener pastures. Sayonara!
 








How could any of you believe that this was a worthwhile gamble???? No sympathy for any of you, sorry to be a douche but this was doomed to fail before it started - 240 reps, account executives (worthless, totally worthless wastes of money) and a product that is one step easier to take than boceprevir. I kicked the tires last year and the retread of a hiring manager was all I needed to come to the conclusion to pass on it.